Dimensional Fund Advisors
TCRX icon

Dimensional Fund Advisors’s TScan Therapeutics TCRX Stock Holding History

Dimensional Fund Advisors’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-65,335
Closed -$64K – 3284
2026
Q2 		$64K Hold
65,335
– – ﹤0.01% 3178
2026
Q1 		$65.8K Sell
65,335
-9,132
-12% -$9.8K ﹤0.01% 3156
2025
Q4 		$74.5K Sell
74,467
-12,849
-15% -$18.6K ﹤0.01% 3184
2025
Q3 		$159K Sell
87,316
-42,540
-33% -$75.4K ﹤0.01% 3148
2025
Q2 		$188K Sell
129,856
-140,243
-52% -$203K ﹤0.01% 3123
2025
Q1 		$373K Sell
270,099
-9,929
-4% -$21.5K ﹤0.01% 3038
2024
Q4 		$851K Buy
280,028
+145,731
+109% +$661K ﹤0.01% 2949
2024
Q3 		$669K Buy
134,297
+122,415
+1,030% +$739K ﹤0.01% 2980
2024
Q2 		$70.5K Buy
+11,882
New +$93.6K ﹤0.01% 3284

Other funds holding TCRX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $741K AUM 2.77% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Marshall Wace
Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Dimensional Fund Advisors's TCRX Position: Q3 2026 in Review

Dimensional Fund Advisors sold out of TScan Therapeutics (TCRX) in Q3 2026, closing a stake of 65,335 shares — an estimated $64K sold.

Dimensional Fund Advisors first reported a position in TCRX in Q2 2024 and held it in 9 quarters. The position peaked at $851K in Q4 2024. 33 funds tracked by Wall St. Rank hold TCRX as of Q3 2026.

  • Dimensional Fund Advisors reported no remaining TScan Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Dimensional Fund Advisors sold 65,335 TScan Therapeutics shares in Q3 2026, an estimated $64K.
  • Dimensional Fund Advisors first reported a position in TScan Therapeutics in Q2 2024 and held it in 9 quarters.
  • Dimensional Fund Advisors's TScan Therapeutics position peaked at $851K in Q4 2024.
  • 33 funds tracked by Wall St. Rank held TScan Therapeutics as of Q3 2026.

Based on Dimensional Fund Advisors's 13F filing for Q3 2026, filed 4 Nov 2026.